Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 9;2(4):e00046. doi: 10.1002/prp2.46

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Dose-related effects on ragweed-induced pulmonary resistance and heart rate and blood pressure by GS-5759 and indacaterol in beagle dogs. (A) Data represent the mean ± SEM of the percent inhibition of ragweed antigen-induced bronchoconstriction in sensitized dogs compared to vehicle treatment of the same animals 7–14 days previously, n = 4 animals per group. GS-5759 at 18.2 μg/kg is the molar equivalent to indacaterol (IND) at 10.6 μg/kg and salmeterol (SALM) at 9.4 μg/kg. GS-5759 at 1.4 and 5.5 μg/kg is the molar equivalent to indacaterol at 1.0 and 3.2 μg/kg. (B, C) Data represent the mean ± SEM for heart beats per minute (B) and mean blood pressure (C) in beagle dogs following treatment with vehicle, GS-5759 or indacaterol (vehicle-treated dogs n = 8, GS-5759 or indacaterol-treated dogs n = 3–4), *P < 0.05, **P < 0.01 compared to vehicle treatment.